Biosmelt Pharma

Shanghai-based cell and gene therapy (CGT) specialist, Biosmelt Pharma, has entered into a partnership with Shenzhen Eureka Biotechnology Co., Ltd, a domestic CGT-focused Contract Development and Manufacturing Organization (CDMO) service provider. Combining Expertise for Large-Scale Virus Vector ProductionThe collaboration aims to capitalize on Biosmelt’s GMP grade lentivirus vector suspension production…